194 related articles for article (PubMed ID: 30277164)
1. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
[TBL] [Abstract][Full Text] [Related]
2. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
5. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
Vaughn DJ; Srinivas S; Stadler WM; Pili R; Petrylak D; Sternberg CN; Smith DC; Ringuette S; de Wit E; Pautret V; George C
Cancer; 2009 Sep; 115(18):4110-7. PubMed ID: 19536904
[TBL] [Abstract][Full Text] [Related]
6. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Bellmunt J; Théodore C; Demkov T; Komyakov B; Sengelov L; Daugaard G; Caty A; Carles J; Jagiello-Gruszfeld A; Karyakin O; Delgado FM; Hurteloup P; Winquist E; Morsli N; Salhi Y; Culine S; von der Maase H
J Clin Oncol; 2009 Sep; 27(27):4454-61. PubMed ID: 19687335
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
[TBL] [Abstract][Full Text] [Related]
11. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
12. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
Hussain SA; Ansari J; Huddart R; Power DG; Lyons J; Wylie J; Vilarino-Varlela M; Elander NO; McMenemin R; Pickering LM; Faust G; Chauhan S; Jackson RJ
Int J Oncol; 2017 Mar; 50(3):768-772. PubMed ID: 28098864
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
16. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
17. [Vinflunine: still an option for patients with advanced urothelial carcinoma following immune-checkpoint inhibitors?].
Banna GL; Rundo F; Lipari H; Di Quattro R; Urzia V; Libra M; Malatino L
Recenti Prog Med; 2019 Dec; 110(12):615-618. PubMed ID: 31909764
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
Pappot H; von der Maase H; Ullén A; Agerbæk M;
Invest New Drugs; 2018 Aug; 36(4):615-618. PubMed ID: 29081023
[TBL] [Abstract][Full Text] [Related]
20. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
